Swiss CDMO Lonza said it has purchased a clinical-stage manufacturing site in Hayward, California, from Shire.

Investors have had a pointed question for Credit Suisse analysts lately: Is Pfizer buying Bristol-Myers Squibb a question of when, not if?

Catalent has agreed to pay $950 million to buy Cook Pharmica and its extensive biologics manufacturing operation in Bloomington, Indiana.

China’s 3SBio, in a joint venture with CPE Funds, seeks to buy Canadian CDMO Therapure Biomanufacturing for $290 million pending shareholder approval.

Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, weeks after Lonza completed its $5.5 billion buyout of Capsugel.

Three weeks after announcing it would cut 350 jobs at two plants in Israel, Teva has already adjusted that number to 285.

India-based Alembic Pharmaceuticals is selling its formulation manufacturing plant in Baddi to Scott Edil Pharmacia for an undisclosed amount.

Shareholders of India’s Gland Pharma, an injectables manufacturer, are said to be considering selling a 74% stake to China’s Fosun Pharma as a hedge against…

Trump wants to lower the tax burden for companies bringing cash back to the U.S. from overseas, but repatriation may not spur M&A.